MaaT Pharma Announces 18 Million Euro Global Offering and Strategic Developments

MaaT Pharma, a key player in microbiome ecosystem therapies for cancer patients, declared an 18 million euro capital raise through a new share offering. This includes approximately 17 million euros from an institutional Reserved Offering and a retail-focused PrimaryBid Offering, with current shareholders and directors committing 14.4 million euros.

The offering incorporates the release of 125,000 existing shares by Seventure Partners, priced at 8 euros each. Notably, the global offering will further finance the completion of a Phase 3 MaaT013 trial in Europe, with results expected by the end of 2024, and the expansion into the U.S. market.

Seventure Partners, alongside other historic investors like Bpifrance Investissement and Biocodex, have shown robust support through substantial financial commitments. This strategic financial move aims to support ongoing R&D efforts, facilitate broader clinical trials, and ensure operational funding into early Q1 2025.

Closing dates for the offerings are set, with the PrimaryBid Offering closing on May 14, 2024, and the Reserved Offering on the following day. The funds raised will also address debt repayments and general corporate needs, ensuring MaaT Pharma's continued innovation in microbiome-based therapies.